We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
151
CALL
Scholar Rock
SRRK
$5.88B
– –
-362,300
Closed -$6.43M
TARS icon
152
CALL
Tarsus Pharmaceuticals
TARS
$2.55B
– –
-100,000
Closed -$3.63M
TRML
153
CALL
DELISTED
Tourmaline Bio
TRML
– –
-179,200
Closed -$4.1M
TYRA icon
154
Tyra Biosciences
TYRA
$1.85B
– –
-501
Closed -$8.22K
VKTX icon
155
PUT
Viking Therapeutics
VKTX
$3.88B
– –
-200,000
Closed -$16.4M
XBI icon
156
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-700,000
Closed -$66.4M
ASLN
157
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-4,428
Closed -$6.27K
ALPN
158
CALL
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-103,000
Closed -$4.08M
ALPN
159
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-261,365
Closed -$10.4M
MRNS
160
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-303,200
Closed -$2.74M
MRNS
161
PUT
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-212,200
Closed -$1.92M
FNCH
162
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
– –
-6,892
Closed -$18.1K
LBPH
163
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-236
Closed -$5.1K
3 4 5 6
7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.